Propanc Biopharma, Inc.

Latest News

Aug 21, 2024

Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest

Two Publications Reach 10 Citations & 4,500 Reads, Respectively MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical…

View All Press Releases

Aug 14, 2024

Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America

Jul 17, 2024

Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors

Jun 25, 2024

Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office
Latest Publication Blocking Tumor Support from Cancer-Associated Fibroblasts in Tumor Microenvironment View All Publications
Trypsinogen and chymotrypsinogen: potent anti- tumor agents
Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting
Antitumour efficacy of chymotrypsinogen and trypsinogen